Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve
Authors:
Open Access
- 16 November 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-16
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal demyelination in the brain and spinal cord. Studies showed that iron released during the course of myelin breakdown exacerbates tissue damage, which is in agreement with the features of iron-dependent cell death, ferroptosis. Here, we aimed to investigate the possible contribution of ferroptosis in the demyelinated optic nerve, and to explore the effectiveness of ferroptosis inhibitor, deferiprone (DFP), on the extent of demyelination, inflammation and axonal damage. For this purpose, focal demyelination was induced by injection of lysolecithin (LPC), into the optic nerve of male C57BL/6J mice. Afterward, optic nerves were harvested at different time points from as early as 6 h up to 7 days post-LPC injection. Next, to evaluate the effectiveness of DFP two groups of animals received daily intraperitoneal injection of DFP for 3 or 7 continuous days. Vehicle groups received saline. Iron deposition was observed at different time points post-LPC injection from 6 h to 7 days post injection. Examining ferroptosis markers showed a significant reduction in glutathione content along with increased level of malondialdehyde and upregulated ferroptosis marker genes at early time points after injection. Besides, DFP treatment during the inflammatory phase of the model resulted in decreased microgliosis and inflammation. Reduced demyelination, microgliosis and astrogliosis was shown in mice that received DFP for 7 days. Moreover, DFP protected against axonal damage and retinal ganglion cells loss. Our results suggest the possible contribution of ferroptosis pathway in the process of demyelination. The therapeutic strategies targeting iron deposition, e.g. DFP treatment might thus represent a promising therapeutic target for patients with MS.Keywords
Funding Information
- Tarbiat Modares University (Med79865, IG-39803, Med79865, IG-39803)
- Iran National Science Foundation (INSF4004518)
This publication has 70 references indexed in Scilit:
- Engrafted Human Induced Pluripotent Stem Cell-Derived Anterior Specified Neural Progenitors Protect the Rat Crushed Optic NervePLOS ONE, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Oxidative damage in multiple sclerosis lesionsBrain, 2011
- The Oral Iron Chelator Deferiprone Protects against Iron Overload–Induced Retinal DegenerationInvestigative Ophthalmology & Visual Science, 2011
- The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytesJournal of Neuroinflammation, 2011
- Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammationJournal of Neuroinflammation, 2011
- Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administrationJournal of Neural Transmission, 2010
- Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damageBiochimica et Biophysica Acta (BBA) - General Subjects, 2010
- Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple SclerosisJournal of Neuroimaging, 2009
- Oligodendrocytes and myelination: The role of ironGlia, 2008